HarrisCom Blog

My client Scientia Advisors has released a fascinating new review on healthcare opportunities in China.

 Based on primary and secondary research including interviews, third-party reports and several trips to Asia, Scientia foresees exponential growth in diagnostics and major opportunities in medical devices and healthcare information technology (HIT). 

However, Scientia cautions that to succeed in the Chinese marketplace, companies must understand the changing Chinese health care system  and how government reforms will impact growth.

“In recent years, the Chinese government has sought to expand access to care and cut costs,” said Harry Glorikian, managing partner of  Scientia Advisors.

Reforms will increase funding for public hospitals, decentralized care, infrastructure development and public medical insurance, according to the Scientia industry review.  At the same time, the government will tighten the management and oversight of medical institutions, health insurers, pharmaceutical companies and retailers, and will more closely monitor the safety of water, food and the workplace.

“These changes, along with increasing incidence of diabetes, heart disease and various infectious diseases,  are opening opportunities for point-of-care, molecular diagnostics, food and water testing, and HIT in China,” Glorikian said. “But new regulations will lead to lower prices for certain products.”

The review highlights expected double-digit  growth in diagnostics–especially molecular and point-of-care; 25 per cent growth in health information technology; and 20 per cent growth in patient-monitoring equipment and other devices–given that 75 per cent of  medical equipment in China is at least  20 years old.

The review is available for download at www.scientiaadv.com–or contact me for more information!
–Anita Harris

HarrisCom blog is a publication of the Harris Communications Group of Cambridge, MA. We also publish New Cambridge Observer